Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Dendreon
Subjects will receive product as described in the sipuleucel-T approved label. The registry will be strictly observational and thus no additional clinical visits or laboratory tests will be conducted beyond normal clinical practice. Investigators will be asked to record information that becomes available in the normal course of clinical management.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
subjects must be at least 18 years of age
subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent their first leukapheresis for manufacture of sipuleucel-T ≤ 6 months prior to enrollment
subjects must understand and sign an informed consent form
You may not be if
none
Clareo Health | A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
